Natural history of HIV-1 infection and predictors of survival in a cohort of HIV-1 seropositive injecting drug users

Journal of the National Medical Association

Volumn 88, Issue 1, 1996, Pages 37-42

  Brown Jr , Lawrence S ^a   Siddiqui, Nadeem S ^b   Chu, Alvin F ^b  

^a Addiction Research and Treatment Corporation   (United States)

^b NONE

Author keywords

Acquired immunodeficiency syndrome (AIDS); Human immunodeficiency virus (HIV); Injecting drug abusers

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SEXUAL BEHAVIOR; SUBSTANCE ABUSE; SURVIVAL; UNITED STATES;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEW YORK CITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS;

EID: 0029685140     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Center for Disease Control and Prevention. HIV/AIDS Surveillance Report. 1994;6(1):1-27.
2. Brown LS, Chu A, Nemoto T, Ajuluchukwu D, Primm BJ. Human immunodeficiency virus infection in a cohort of intravenous drug users in New York City. NY State J Med. 1989;89:506-510.
3. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457-481.
4. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society. 1972;34:187-220.
5. Fischl MA, Richman DD, Grieco MH, Gottlieb MV, Volberding PA, Laskin OL, et al. The efficacy of azidthymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;317:185-191.
6. Volberding PA, Lagakos SW, Koch MA, Pertinelli C, Meyers MW, Booth DK, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322:941-949.
7. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med. 1990;112:727-737.
8. Fischl MA, Parker CB, Pettinelli C, Wilfsohn M, Hirsch MS, Collier AC, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with acquired immunodeficiency syndrome. N Engl J Med. 1990;323:1009-1014.
9. Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection: results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992;326:437-443.
10. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou S, et al. A controlled trial comparing zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med. 1992;327:581-587.
11. Selwyn PA, Alcabes P, Hartel D, Buono MS, Schoenbaum EE, Klein RS, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992;327: 1697-1703.
12. Moss AR. Laboratory markers as potential surrogates for clinical outcomes in AIDS trials. J Acquir Immune Defic Syndr. 1990;3(suppl):S69-S71.
13. Cohen J. Searching for markers on the AIDS trail. Science. 1992;258:388-390.
14. Fleming T. Evaluating therapeutic interventions; some issues and experiences. Statistical Science. 1992;7:428-456.
15. De Gruttola V, Wulfsohn M, Fischl MA, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr. 1993;6:359-365.
16. Choi S, Lagakos SW, Schooley RT, Volberding P. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med. 1993;118:674-680.
17. Easterbrook PJ, Emand J, Moyle G, Gazzard BG. Progressive CD4 cell depletion and death in zidovodine-treated patients. J Acquir Immune Defic Syndr. 1993;6:927-929.
18. Melnick SL, Renslow S, Thomas LA, Hillman D, Rodriguez EM, Lackman C, et al. Survival and disease progression according to gender of patients with HIV infection. JAMA. 1994;272:1915-1921.
19. Mientjes GH, Medema F, Van Ameijden EJ, et al. Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS. 1991;5:35-41.
20. Des Jarliais DC, Friedman SR, Marmor M, et al. Development of AIDS, HIV seroconversion and potential co-factors for T4 cell loss in a cohort of intravenous drug abusers. AIDS. 1987;1:105-111.
21. Rezza G. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. The Italian Seroconversion Study. AIDS. 1992;6:421-426.
22. Kaslow RA, Blackwelder WC, et al. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. A report from the multicenter AIDS cohort study. JAMA. 1989;261:3424-3429.
23. Sande MA, Carpenter CJ, Cobbs G, Holmes KK, Sandford JP; for the National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. Antiretroviral therapy for adult HIV infected patients. JAMA. 1993;270:2583-2589.
24. Alboulker JR, Swart AM. Preliminary analysis of the Concorde Trial. Lancet. 1993;341:889-890.
25. Lange JMA. A placebo-controlled clinical trial of zidovudine in asymptomatic HIV infected individuals. Presented at the Third European Conference on the Clinical Aspects of HIV Infection; March 12-13, 1992; Paris, France.
26. Neaton JD, Wentworth DN, Rhame F, Hogan C, Abrams DI, Deyton L. Methods of studying interventions considerations in choice of a clinical endpoint for AIDS clinical trials. Stat Med. 1994;13:2107-2125.
27. Abrams DI. Survival: the ultimate endpoint. In: Abrams D, Cotton D, Mayer K, eds. AIDS/HIV Treatment Directory. New York, NY; American Foundation for AIDS Research. 1993;6(2):S-11.
28. Lenderking WR, Gelber R, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med. 1994;330:738-743.
29. Freeman HP. The impact of clinical trial protocols on patient care systems in a large city hospital. Cancer. 1993;72(suppl):2834-2838.
30. Des Jarlais DC, Friedman SR. HIV infection among intravenous drug users: epidemiology and risk reduction. AIDS. 1987;1:67-76.
31. Friedman SR, Des Jarlais DC, Sotheran JL, Garber J, Cohen H, et al. AIDS and self-organization among intravenous drug users. Int J Addict. 1987;22:201-220.
32. Des Jarlais DC. The first and second decades of AIDS among injecting drug users. British Journal of Addiction. 1992;87:347-353.
33. Siddiqui NS, Brown LS, Meyer TJ, Gonzalez V. Decline in HIV-1 seroprevalence and low seroconversion rate among injecting drug users at a methadone maintained program in New York City. J Psychoactive Drugs. 1993;23:245-250.
34. Siddiqui NS, Brown LS, Phillips RY, Vargas O, Makuch RW. No seroconversions among steady sex partners of HIV-1-seropositive injecting drug users in New York City. AIDS. 1992;6:1529-1533.